

A1  
Amended. antagonist is contained in a formulation or medicament intended for administration in a quantity of 1 to 75 wt.%, preferably 5 to 50 wt.%, preferably 5 to 25 wt.%.

A2  
Claim 18. (Amended) The process [Process] according to claim 17, characterized by [at least one of the features of claims 2 to 16] the features of claim 2.

A3  
Claim 20. (Amended) The composition [Composition] or medicament according to claim 19, characterized by [at least one of the features of claims 7 to 16] the features of claim 7.

REMARKS

00E020" E690E55  
Claims 1-20 are pending in the present application. The amendments do not add any new matter under 35 U.S.C. §132. The amendments have been made to remove multiple dependencies from the claims and to convert the use claims into method claim format. Accordingly, entry of the amendments prior to examination of the application is respectfully requested.

CONCLUSION

In view of the foregoing, Applicants respectfully request the Examiner to allow all claims pending in this application. If the Examiner has any questions or wishes to discuss this matter, the Examiner is welcomed to telephone the undersigned attorney.

ZENNER et al.

**NATH & ASSOCIATES PLLC**

Date: May 4, 2000  
NATH & ASSOCIATES PLLC  
1030<sup>th</sup> Street, NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005-1503  
GMN:JLM:JBG:\AMENDpremPCT2

Gary M. Nath  
Reg. No. 26,965  
Customer No. 20529

[illegible]